CA2863291A1 - Romidepsin formulations and uses thereof - Google Patents

Romidepsin formulations and uses thereof Download PDF

Info

Publication number
CA2863291A1
CA2863291A1 CA2863291A CA2863291A CA2863291A1 CA 2863291 A1 CA2863291 A1 CA 2863291A1 CA 2863291 A CA2863291 A CA 2863291A CA 2863291 A CA2863291 A CA 2863291A CA 2863291 A1 CA2863291 A1 CA 2863291A1
Authority
CA
Canada
Prior art keywords
romidepsin
administered
formulation
certain embodiments
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2863291A
Other languages
English (en)
French (fr)
Inventor
Lianfeng Huang, Iii
Ho-Wah Hui
Victor Peykov
Willard R. Foss
Vijay Naringrekar
Mei Lai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CA2863291A1 publication Critical patent/CA2863291A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2863291A 2012-01-12 2013-01-11 Romidepsin formulations and uses thereof Abandoned CA2863291A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586066P 2012-01-12 2012-01-12
US61/586,066 2012-01-12
PCT/US2013/021212 WO2013106696A1 (en) 2012-01-12 2013-01-11 Romidepsin formulations and uses thereof

Publications (1)

Publication Number Publication Date
CA2863291A1 true CA2863291A1 (en) 2013-07-18

Family

ID=47604232

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2863291A Abandoned CA2863291A1 (en) 2012-01-12 2013-01-11 Romidepsin formulations and uses thereof

Country Status (8)

Country Link
US (3) US20130184225A1 (https=)
EP (1) EP2802340B1 (https=)
JP (1) JP6170946B2 (https=)
CN (1) CN104168908A (https=)
AU (1) AU2013201937B8 (https=)
CA (1) CA2863291A1 (https=)
MX (1) MX2014008390A (https=)
WO (1) WO2013106696A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630311A (en) * 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN106137980B (zh) * 2015-03-31 2021-04-13 深圳翰宇药业股份有限公司 一种罗米地辛脂微球制剂及其制备方法
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
KR20200141446A (ko) * 2018-04-05 2020-12-18 타베다 세라퓨틱스, 인코포레이티드 감소된 3급-부탄올 수준을 갖는 약제학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH0764872A (ja) 1993-08-26 1995-03-10 Fujitsu Ten Ltd データ記憶制御装置
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
HK1040062A1 (zh) * 1999-03-03 2002-05-24 Eli Lilly And Company 含有成胶束表面活性剂的棘白菌素药物配方
US7396665B2 (en) 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
DK2238982T3 (da) * 2003-06-27 2013-01-28 Astellas Pharma Inc Terapeutisk middel til blødt væv-sarcom
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
EP2450049A1 (en) * 2006-12-29 2012-05-09 Gloucester Pharmaceuticals, Inc. Romidepsin-based treatments for cancer
WO2008127659A2 (en) * 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer
JP2010105965A (ja) * 2008-10-30 2010-05-13 Taiyo Yakuhin Kogyo Kk バンコマイシン製剤
SG10201407724YA (en) * 2009-11-23 2014-12-30 Cubist Pharm Inc Daptomycin compositions and related methods
SG10201505475XA (en) 2010-07-12 2015-09-29 Celgene Corp Romidepsin solid forms and uses thereof

Also Published As

Publication number Publication date
JP2015503623A (ja) 2015-02-02
US20130184225A1 (en) 2013-07-18
MX2014008390A (es) 2014-09-22
US20160367625A1 (en) 2016-12-22
AU2013201937A1 (en) 2013-08-01
AU2013201937B8 (en) 2015-08-20
EP2802340A1 (en) 2014-11-19
WO2013106696A1 (en) 2013-07-18
EP2802340B1 (en) 2020-10-28
JP6170946B2 (ja) 2017-07-26
AU2013201937A8 (en) 2015-08-20
CN104168908A (zh) 2014-11-26
US20150051157A1 (en) 2015-02-19
AU2013201937B2 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
US9980957B2 (en) Histone deacetylase (HDAC) inhibitors for the treatment of cancer
US20160367625A1 (en) Romidepsin formulations and uses thereof
ES2773315T3 (es) Formulación de AC220 secada por pulverización
ES2436266T3 (es) Métodos para administrar N-(5-terc-butil-isoxazol-3-il)-N'-{4-[7-(2-morfolin-4-il-etoxi)imidazo[2,1-b][1,3]benzotiazol-2-il]fenil}urea para tratar enfermedades proliferativas
ES2655820T3 (es) Formulación que comprende un profármaco de gemcitabina
US9782451B2 (en) Romidepsin formulations and uses thereof
TW202227090A (zh) 四環喹諾酮類似物及其鹽類的藥物組合物
CN119233821A (zh) Pi3k抑制剂与pd-1抑制剂的组合疗法
TW202228719A (zh) 含有引發血管病變之水溶性藥之組合物、含有引發血管病變之水溶性藥之投予液調製用溶液、套組、血管病變抑制劑、及含有非離子型界面活性劑之溶液
AU2013205999A1 (en) Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190111